|
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with temozolomide may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when given together with temozolomide in treating patients with brain tumors or other solid tumors that have not responded to treatment.
U.S. FDA Resources
Further study details as provided by National Cancer Institute (NCI): Primary Outcome Measures:
Secondary Outcome Measures:
Detailed Description: OBJECTIVES: Primary
Secondary
OUTLINE: Patients are stratified according to concurrent hepatic enzyme-inducing anticonvulsants (HEIAs) (Group A) versus concurrent anticonvulsant drugs that cause modest or no induction of hepatic metabolic enzymes OR no anticonvulsant drugs (Group B).
All patients undergo blood sample collection periodically for pharmacokinetic studies. Samples are analyzed for bortezomib concentration (groups A and B) and trough levels of anticonvulsants (group A only). Eligibility
Criteria DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Inclusion criteria:
Exclusion criteria:
PRIOR CONCURRENT THERAPY: Inclusion criteria:
Exclusion criteria:
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00544284 Locations
Sponsors and Collaborators
Investigators
More Information
Keywords provided by National Cancer Institute (NCI):
Study placed in the following topic categories:
Additional relevant MeSH terms:
Source: National Library of Medicine (NLM) July 02, 2008 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Browse All News Categories
Business
|
Consumer
|
Education
|
Entertaiment
|
Family & Community
|
Health
|
Law
|
Offbeat
|
Politics
|
Science
|
Sports
|
Technology
|
Weather
|
World News
|
||
|
News Archive
|
||


